ERYTECH Pharma S.A.
Develops red blood cell-based therapies for cancer and orphan diseases.
ERYP | PA
Overview
Corporate Details
- ISIN(s):
- FR0010417360 (+2 more)
- LEI:
- 969500U8ZZCODU8A9374
- Country:
- France
- Address:
- 60 AVENUE ROCKEFELLER, 69008 LYON
- Website:
- https://phaxiam.com/
- Sector:
- Manufacturing
Description
ERYTECH Pharma S.A. is a clinical-stage biopharmaceutical company that develops innovative therapeutics based on its proprietary ERYCAPS platform, which encapsulates drug substances inside red blood cells. This technology is designed to improve the efficacy and safety of treatments by prolonging the drug's circulation time and reducing side effects. The company's primary focus is on developing treatments for severe forms of cancer and orphan diseases. Its lead product candidate, eryaspase, encapsulates the enzyme L-asparaginase to starve cancer cells of essential nutrients, targeting indications such as acute lymphoblastic leukemia and pancreatic cancer.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2018-04-24 22:30 |
Document availability communications / Annual financial report
|
English | 232.1 KB | ||
| 2018-04-24 22:30 |
Communiqués de mise à disposition de documents / Modalités de mise à dispositio…
|
French | 250.3 KB | ||
| 2018-04-16 16:30 |
Communicated under the obligation to provide permanent information / Other comm…
|
English | 194.4 KB | ||
| 2018-04-16 16:30 |
Communiqués au titre de l'obligation d'information permanente / Autres communiq…
|
French | 441.2 KB | ||
| 2018-03-13 21:30 |
Communicated under the obligation to provide permanent information / Activity o…
|
English | 547.7 KB | ||
| 2018-03-13 21:30 |
Communiqués au titre de l'obligation d'information permanente / Activité de l'é…
|
French | 697.7 KB | ||
| 2018-03-07 07:30 |
Communicated under the obligation to provide permanent information / Activity o…
|
English | 193.6 KB | ||
| 2018-03-07 07:30 |
Communiqués au titre de l'obligation d'information permanente / Activité de l'é…
|
French | 441.0 KB | ||
| 2018-02-13 07:30 |
Communicated under the obligation to provide permanent information / Activity o…
|
English | 256.2 KB | ||
| 2018-02-13 07:30 |
Communiqués au titre de l'obligation d'information permanente / Activité de l'é…
|
French | 264.7 KB | ||
| 2018-02-12 18:16 |
Communicated under the obligation to provide permanent information / Other comm…
|
English | 193.5 KB | ||
| 2018-02-12 18:16 |
Communiqués au titre de l'obligation d'information permanente / Autres communiq…
|
French | 439.7 KB | ||
| 2018-02-08 07:30 |
Communiqués au titre de l'obligation d'information permanente / Activité de l'é…
|
French | 424.1 KB | ||
| 2018-02-08 07:30 |
Communicated under the obligation to provide permanent information / Activity o…
|
English | 290.7 KB | ||
| 2018-01-08 13:54 |
Information relative au nombre total de droits de vote et d'actions composant l…
|
French | 455.3 KB |
Automate Your Workflow. Get a real-time feed of all ERYTECH Pharma S.A. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for ERYTECH Pharma S.A.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for ERYTECH Pharma S.A. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2023-06-23 | N/A | Other | Other | 3,697,533 | 2,255,495.13 EUR |
| 2023-06-23 | N/A | Other | Other | 71,839 | 43,821.79 EUR |
| 2023-06-23 | N/A | Other | Other | 54,862 | 33,465.82 EUR |
Peer Companies
